Navigation Links
Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer

ancer

According to the American Cancer Society, 81,550 Americans will be diagnosed with head and neck cancer in 2007, including cancers of the tongue, the rest of the mouth, the salivary glands and inside the throat, the voice box, eye and orbit, thyroid and the lymph nodes in the upper neck. In addition, it is estimated that more than 12,900 Americans will die from this disease this year. Head and neck cancer most often affects people over the age of 50, and men are twice as likely to be diagnosed as women. The most common risk factors are tobacco and excessive alcohol use.

About ERBITUX(R) (Cetuximab)

ERBITUX is a monoclonal antibody (IgG1 Mab) designed to inhibit the function of a molecular structure expressed on the surface of normal and tumor cells called the epidermal growth factor receptor (EGFR, HER1, c-ErbB-1). In vitro assays and in vivo animal studies have shown that binding of ERBITUX to the EGFR blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, and decreased matrix metalloproteinase and vascular endothelial growth factor production. In vitro, ERBITUX can mediate antibody-dependent cellular cytotoxicity (ADCC) against certain human tumor types. While the mechanism of ERBITUX' anti-tumor effect(s) in vivo is unknown, all of these processes may contribute to the overall therapeutic effect of ERBITUX. EGFR is part of a signaling pathway that is linked to the growth and development of many human cancers, including those of the head and neck, colon and rectum.

ERBITUX (Cetuximab), in combination with radiation therapy, is indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck. ERBITUX as a single agent is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck for whom prior platinum-based therapy has failed.

ERBITUX is indicated for
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
5. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
6. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
7. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
8. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
9. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
10. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
11. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
Post Your Comments:
(Date:7/22/2014)... , July 22, 2014 The number of ... 45 people each day. Twenty-three percent of the workforce ... on Drug Use and Health, making opioid use a ... taking opioid painkillers at the correct dosage with a ... Today, the National Safety Council released ...
(Date:7/22/2014)... July 22, 2014 BiologicTx ® today ... first 3-way Kidney Paired Donation transplant exchange utilizing BiologicTx,s ... on July 9 at the Miami Transplant Institute, located ... Kidney Paired Donation (KPD) ... compatible for kidney transplant with one another due to ...
(Date:7/22/2014)... , July 22, 2014 Elekta (NSE:EKTAb) and ... that The Christie NHS Foundation Trust ( Manchester, ... a consortium whose mission is to develop the clinical ... radiation therapy system. Such a system would, in principle, ... cancer targets. "The Christie was an ...
Breaking Medicine Technology:5 things employers should know about prescription painkiller use 25 things employers should know about prescription painkiller use 3BiologicTx Paired Donation Aids In Successful Kidney Transplants 2BiologicTx Paired Donation Aids In Successful Kidney Transplants 3The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 2The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 3The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 4
... 1 Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: ... a quarterly royalty payment of approximately $1.5 million ... Memantine for the treatment of Alzheimer,s disease. Under ... royalty payments on certain sales of Memantine by ...
... Inc. (OTC Bulletin Board: SCIE) , a San Diego based ... an article reporting that its LUMA cervical imaging system is enhancing ... . Since Last July, researchers at the University ... LUMA Cervical Imaging System in more than 80 women - in ...
Cached Medicine Technology:Des Moines Register Reports SpectraScience LUMA Enhances Cervical Cancer Exams 2Des Moines Register Reports SpectraScience LUMA Enhances Cervical Cancer Exams 3
(Date:7/22/2014)... 22, 2014 The market for botulinum ... few years, owing to novel medical indications created and ... the aging societies where physical appearance is extremely valued. ... player, current competitors, new companies and technologies are setting ... BoNTs will put the price of 1st-gen products under ...
(Date:7/22/2014)... July 22, 2014 CarePoint Health is pleased ... as the President of the medical staff at Bayonne Medical ... serve as President, as voted on by the physicians on ... medical staff in relation to the administration at Bayonne Medical ... physicians and to work to make the Medical Center the ...
(Date:7/22/2014)... The Middle East Drilling fluid and Completion ... completion fluid market in Middle East with analysis and forecast ... Middle East is estimated to grow from around $560 million ... of 5.7%, for the given period. , Browse through the ... Market report, to get an idea of the in-depth analysis ...
(Date:7/22/2014)... 22, 2014 Over the years, ... every sphere of human anatomy. In the pursuit, ... that rendered the possibility of deploying certain tests ... and tissues, in order to detect the presence ... Essentially, In-vitro Diagnostics (IVD) have earned the title ...
(Date:7/22/2014)... time? How can women meet the demands of a ... become a mother has a profound effect on the ... the physical sciences. Yet many women successfully manage to ... Professor, fifteen inspirational personal accounts describe the challenges and ... chemistry. , The authors of the contributions are all ...
Breaking Medicine News(10 mins):Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 2Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 3Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 4Health News:Dr. Howard Levine Elected President of the Medical Staff at Bayonne Medical Center 2Health News:Middle East Drilling Fluid & Completion Fluid Market is Expected to Reach $740 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Middle East Drilling Fluid & Completion Fluid Market is Expected to Reach $740 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Middle East Drilling Fluid & Completion Fluid Market is Expected to Reach $740 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Middle East Drilling Fluid & Completion Fluid Market is Expected to Reach $740 Million in 2018 - New Report by MicroMarket Monitor 5Health News:Middle East Drilling Fluid & Completion Fluid Market is Expected to Reach $740 Million in 2018 - New Report by MicroMarket Monitor 6Health News:Global Molecular Diagnostics Market Report 2014 Edition Now Available at MarketReportsOnline.com 2Health News:Global Molecular Diagnostics Market Report 2014 Edition Now Available at MarketReportsOnline.com 3Health News:Global Molecular Diagnostics Market Report 2014 Edition Now Available at MarketReportsOnline.com 4
... 4 Over 100 million Americans,are plagued by high cholesterol, ... the Healthy Monday campaign suggests Americans take the,idea of Fat ... from,meat-heavy, high-fat diets., "Carnival" has its roots in the ... Eating a little less meat can be a big,step towards ...
... Deal follows positive phase I data from novel product ... the ... 4 Amira Pharmaceuticals and,GlaxoSmithKline today announced they have ... commercialize FLAP,(5-Lipoxygenase Activating Protein ) inhibitors for the treatment ...
... 4 The Providence Service,Corporation (Nasdaq: PRSC ... Executive Officer, is scheduled to present an overview ... Services Conference on,Monday, February 11, 2008 at the ... presentation is scheduled for 12:00 p.m. EST. The,presentation ...
... using shampoo, lotion and powder, study shows , , MONDAY, Feb. ... tested in a new study had been exposed to a ... what this means in terms of infant health isn,t yet ... to be harmful to development, and one study on human ...
... Triple-S,Management Corporation (NYSE: GTS ) today announced that ... Roman,Finance Vice President and Chief Financial Officer, will present ... Conference in,New York City on February 12, 2008, at ... through the Internet and will remain,archived for 90 days. ...
... -, PALO ALTO, Calif., Feb. 4 PEAK ... new category of tissue,dissection systems based on a proprietary ... a Series C financing led by new investor,Signet Healthcare ... of Signet Healthcare Associates, has joined PEAK,Surgical,s board of ...
Cached Medicine News:Health News:Mardi Gras Means Lean Times Ahead But That Doesn't Mean the Party's Over 2Health News:Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program 2Health News:Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program 3Health News:Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program 4Health News:Providence Service Corporation to Present at the 2008 UBS Global Healthcare Services Conference on February 11 2Health News:Many Babies Exposed to Chemicals 2Health News:Many Babies Exposed to Chemicals 3Health News:PEAK Surgical, Inc. Closes $21 Million Series C Financing 2
UST-675-P is our end-fire prostate transducer. Multiple frequencies provide extraordinary imaging capabilities for your diverse patient population, and the biopsy guide enables accurate and fast pros...
Super High Density 360 degree radial rectal transducer. High resolution in the near field and lower frequencies for deeper penetration make this transducer the optimal choice when scanning the anal c...
Our most versatile transducer for superficial imaging. Wide Band, Super High Density, multi-frequency transducer with superb Doppler and color flow sensitivity make this an excellent choice for breas...
... 5545 linear transducer is our high ... superficial and vascular imaging. Multiple frequencies ... sensitivity combined with our exclusive transducer ... PixelFocus to provide excellent resolution and ...
Medicine Products: